Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

50 results about "Nrf2 activation" patented technology

Reporter system for high throughput screening of compounds and uses thereof

The NF-E2-related factor 2 (Nrf2) is a key transcriptional regulator of antioxidant defense and detoxification. To directly monitor stabilization of Nrf2 we fused its Neh2 domain, responsible for the interaction with its nucleocytoplasmic regulator, Keap1, to firefly luciferase (Neh2-luciferase). It is shown herein that Neh2 domain is sufficient for recognition, ubiquitination and proteasomal degradation of Neh2-luciferase fusion protein. The novel Neh2-luc reporter system allows direct monitoring of the adaptive response to redox stress and classification of drugs based on the time-course of reporter activation. The novel reporter was used to screen a library of compounds to identify activators of Nrf2. The most robust and yet non toxic Nrf2 activators found—nordihydroguaiaretic acid, fisetin, and gedunin-induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.
Owner:CORNELL UNIVERSITY

Recombinant plasmid for screening Nrf2 activating agent and construction method and application thereof

The invention relates to the field of biological medicine, in particular to recombinant plasmid for screening an Nrf2 activating agent and a construction method and application thereof. The recombinant plasmid comprises one or two or above series antioxidant reaction elements, basal transcription elements, secretion-type luciferase genes and secretion-type alkaline phosphatase genes. Compared with the prior art, as secretion-type luciferase is used as reporter genes, the detection sensitivity is high, cells do not need to be pyrolysed when the activity of the luciferase genes is detected, high-throughput screening and comparing and detection of the long-term effect of an antioxidant are achieved, and an efficient, rapid, simple and convenient method is provided for screening the antioxidant or detecting the activity of the antioxidant, and the recombinant plasmid can be applied to screening of natural medicine with the antioxidation effect and artificially-synthesized compounds.
Owner:广州市皮肤病防治所

NRF2 activator compound, drugs and new application of atractylenolide II

The invention discloses an NRF2 activator compound, drugs and new application of atractylenolide II, wherein the NRF2 activator compound is the atractylenolide II; the drugs are drugs for treating and preventing the diseases associated with NRF2 pathway regulation, and comprise the component atractylenolide II; the new application of the atractylenolide II is about the use of the atractylenolide II in preparing drugs or foods for treating or preventing the diseases associated with the NRF2 pathway regulation. Through a lot of exploration and research of the inventors, a plurality of compounds are tested and selected, and it is unexpectedly found that the atractylenolide II can be used as an effective NRF2 inducer. The experiments prove that the atractylenolide II can be used in the drugs for treating or preventing the diseases associated with the NRF2 pathway regulation. Particularly, the cell experiments and the animal experiments prove that the atractylenolide II has inhibitory effect on the growth of breast cancer cells.
Owner:SICHUAN UNIV

Nrf2 Activating Compounds and Uses Thereof

Aspects of the present disclosure include compounds that activate Nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Owner:RIGEL PHARMA

Reporter system for high throughput screening of compounds and uses thereof

The NF-E2-related factor 2 (Nrf2) is a key transcriptional regulator of antioxidant defense and detoxification. To directly monitor stabilization of Nrf2 we fused its Neh2 domain, responsible for the interaction with its nucleocytoplasmic regulator, Keap1, to firefly luciferase (Neh2-luciferase). It is shown herein that Neh2 domain is sufficient for recognition, ubiquitination and proteasomal degradation of Neh2-luciferase fusion protein. The novel Neh2-luc reporter system allows direct monitoring of the adaptive response to redox stress and classification of drugs based on the time-course of reporter activation. The novel reporter was used to screen a library of compounds to identify activators of Nrf2. The most robust and yet non toxic Nrf2 activators found—nordihydroguaiaretic acid, fisetin, and gedunin-induced astrocyte-dependent neuroprotection from oxidative stress via an Nrf2-dependent mechanism.
Owner:CORNELL UNIVERSITY

Butyrylcholine esterase selective inhibitor as well as preparation method and application thereof

The invention discloses a butyrylcholine esterase selective inhibitor as well as a preparation method and application thereof. The inhibitor is a compound shown as a formula (I). The invention also discloses application of the compound in preparation of drugs for preventing or treating Alzheimer's disease. Experiments such as butyrylcholine esterase inhibitory activity, selective screening, Nrf2 activation activity, Morris water maze and the like are used as carriers to evaluate the treatment of Alzheimer's disease (especially moderate and severe Alzheimer's disease) by the compound shown in the formula (I), and the compound is found to have good in-vitro and in-vivo activity and extremely high selectivity. The compound can be used as a precursor substance for further development of Alzheimer's disease by selectively inhibiting butyrylcholine esterase.
Owner:CHINA PHARM UNIV

Therapeutic compounds

The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.
Owner:C4X DISCOVERY

BIOMARKER OF Nrf2 ACTIVATION

Provided is FGF21 that is a metabolism-related biomarker reflecting the activation of Nrf2 in vivo. Also provided are a method for monitoring a response of a subject to which an Nrf2 activator is administered, said method comprising a step for measuring the FGF21 level, at a point during or after the administration of the Nrf2 activator, in a biosample that is derived from the subject, wherein an increase in the FGF21 level indicates a positive response to the administration of the Nrf2 activator, etc. According to the present invention, a metabolism-related biomarker that reflects the activation of Nrf2 in vivo is provided.
Owner:MOCHIDA PHARM CO LTD +1

Nitrogen-containing heterocyclic compound having NRF2 activation effect

Provided is a low-molecular compound or a salt thereof, or a solvate thereof which has the ability to activate Nrf2.The present invention provides a compound represented by the formula (1) or a salt thereof, or a solvate thereof, wherein Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2 and Ra3 are each independently selected from the group consisting of hydrogen, halogen and C1-C6 alkoxy, Xb1, Xb2 and Xb3 are each independently selected from the group consisting of CH2, O, NH, S and C═O, Y is C6-C10 aryl optionally having a substituent or 5- to 10-membered heteroaryl optionally having a substituent, and Z is C6-C10 aryl optionally having a substituent, 5- to 10-membered heteroaryl optionally having a substituent or C1-C6 alkyl optionally having a substituent.
Owner:CHUGAI PHARMA CO LTD

1, 2, 4-oxadiazole Nrf2 activator-tacrine spliced product as well as preparation method and application thereof

The invention discloses a 1, 2, 4-oxadiazole Nrf2 activator-tacrine spliced product as well as a preparation method and application thereof. The structure of the compound is shown in the specification. According to the 1, 2, 4-oxadiazole Nrf2 activator-tacrine spliced product as well as the preparation method and application thereof of the invention, acetylcholin esterase inhibitory activity, Nrf2 activation activity, selective screening and Morris water maze experiments are used as carriers to evaluate the treatment of the Alzheimer's disease (especially moderate and severe Alzheimer's disease) by the compounds shown in the general formulas I, II and III, and the compounds have good in-vitro and in-vivo activity and extremely high selectivity, and can be used as precursor substances for further development of an anti-Alzheimer's disease effect by selectively inhibiting acetylcholin esterase and activating Nrf2.
Owner:CHINA PHARM UNIV

Method for high-throughput screening of compound with Nrf2 activating activity

InactiveCN105087644AAdapt to the needs of high-throughput screeningSensitive and fast acquisitionMicrobiological testing/measurementVector-based foreign material introductionEscherichia coliNrf2 activation
The invention relates to a method for high-throughput screening of a compound with Nrf2 activating activity. The method comprises the following steps: (1) establishing a reporter gene containing three Nrf2 binding sites; (2) inserting the reporter gene into plasmids, and thus obtaining reporter gene plasmids; (3) amplifying the reporter gene plasmids by adopting escherichia coli, and purifying the plasmids; and (4) transfecting HeLa cells by adopting the purified reporter gene plasmids, and selecting stable expression cell strains for the selection of an unknown compound. With the adoption of the technical scheme provided by the invention, the method for detecting the activating effect of Nrf2 in the prior art is enabled to adopt to the demand of high-throughput screening at the initial development stage of the new medicine. The traditional method generally needs half a day to two days for completely once of detection, while the quantity of the samples detected by the once experiment does not beyond a dozen. For the method provided by the invention, each 96-pore board can detect at least 10 samples, and the time needed for completing the detection by the 96-pore board is less than 30 minutes.
Owner:SHANDONG UNIV

Use of non-ros-dependent photoenergy enzymes in photocatalysis and nrf2 activation

The application belongs to the field of nanomaterials and biotechnology, and particularly relates to application of non-ROS-dependent photoenzyme in photocatalysis and Nrf2 activation. The preparation method of the non-ROS-dependent photoenzyme is as follows: chloroauric acid is added into a mixed solution of 6-azido-2-thiothymine and sodium hydroxide, and the reaction is stirred at 25-30 DEG C to prepare nanometer photoenzyme; the molar ratio of 6-azido-2-thiothymine to chloroauric acid is (2.1-2.6):1. The non-ROS-dependent nanometer photoenzyme provided by the application has the advantages of simple and efficient synthesis method, ultrahigh photocatalytic activity, non-ROS-dependent catalytic mechanism, excellent biocompatibility, and the ability to realize intracellular light-controlled activation of Nrf2, and solves the problems of ROS-dependent oxidative damage, uncontrollable Nrf2 activation, and over-activation of signal pathways.
Owner:SHANDONG NORMAL UNIV

Therapeutic compounds

The present invention relates to compounds that are Nrf2 activators. The compounds have the structural formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.
Owner:C4X DISCOVERY

Novel sulfanon derivatives or pharmaceutically acceptable salts thereof, and uses thereof

The present invention relates to a sulfanon derivative or a pharmaceutically acceptable salt thereof, and a composition for cancer prevention or treatment containing the derivative as an active ingredient. The sulfanon derivative or a pharmaceutically acceptable salt thereof of the present invention has excellent Nrf2 activation effect, high solubility and drug metabolic stability, anti-inflammatory and antioxidant effects, and improves exercise ability and cognitive ability. Therefore, it is used for the prevention or treatment of diseases induced by the decrease of Nrf2 activity, preferably liver diseases, kidney diseases, lung diseases, neurodegenerative diseases, mitochondrial myopathy, Friedreich's ataxia, corneal endothelial cell reduction, and psoriasis.
Owner:KOREA INST OF SCI & TECH

A licorice chalcone nrf2 small molecule agonist and preparation and application thereof

The application discloses a licorice chalcone NRF2 small molecule agonist and a preparation and application thereof, a structure of the licorice chalcone NRF2 small molecule agonist is shown as formula (I), the compound can be used for preparing a drug for treating tumors, and experimental results show that the compound has better Nrf2 activation activity than licorice chalcone E and has higher anticancer activity.
Owner:WENZHOU MEDICAL UNIV

Hydroxamate triterpenoid derivatives

Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein R═—C(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1α and HIF-2α proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-κB inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors. Said triterpenoid derivatives are useful in the treatment of conditions and diseases which are responsive to HIF activation such as stroke, cerebral palsy, traumatic injuries and neurodegenerative diseases; and also IBD, myocardial ischaemia-reperfusion injury, acute lung injury, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.
Owner:VIVACELL BIOTECH ESPANA

Therapeutic compounds

The present invention relates to compounds that are Nrf2 activators. These compounds have the structural formula IA as defined herein. The invention also relates to intermediate compounds and methods for preparing these compounds, to pharmaceutical compositions comprising these compounds, and to their use in the treatment of diseases or disorders associated with Nrf2 activation.
Owner:C4X DISCOVERY

Application of non-ROS dependent luminous energy enzyme in photocatalysis and Nrf2 activation

The invention belongs to the technical field of nano materials and biology, and particularly relates to application of a non-ROS dependent luminous energy enzyme in photocatalysis and Nrf2 activation. The preparation method of the non-ROS dependent luminous energy enzyme comprises the following steps: adding chloroauric acid into a mixed solution of 6-aza-2-thiothymine and sodium hydroxide, and stirring for reaction at 25-30 DEG C to prepare the nano luminous energy enzyme; the molar ratio of the 6-aza-2-thiothymine to the chloroauric acid is (2.1 to 2.6): 1. The non-ROS-dependent nano light energy enzyme provided by the invention has the advantages of simple and efficient synthesis method, ultrahigh photocatalytic activity, non-ROS-dependent catalytic mechanism and excellent biocompatibility, can realize intracellular light-operated activation of Nrf2, and solves the problems of ROS-dependent oxidative damage, aggravation, uncontrollable Nrf2 activation, excessive activation of signal channels and the like.
Owner:SHANDONG NORMAL UNIV

Compositions for improved NRF2 activation and methods of their use

Disclosed here are compositions and methods for preventing or treating certain health conditions associated with inflammation or oxidative stress. These compositions are prepared from ingredients containing phytochemicals that activate the Nrf2 pathways. Synergistic effects of the different phytochemicals are also disclosed.
Owner:PATHWAYS BIOSCIENCE LLC

Nrf2 Activating Compounds and Uses Thereof

Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Owner:RIGEL PHARMA

Application of inhibitor of Bach1 in preparation of medicine for treating chemotherapy brain injury induced by chemotherapy medicine

The invention discloses an application of a Bach1 inhibitor in preparation of a therapeutic drug for chemotherapy brain injury induced by a chemotherapy drug. The Bach1 inhibitor is prepared from 5-aminolevulinic acid or si-Bach1. In vivo and in vitro studies prove that administration of 5-ALA and overexpression of ALAS2 can prevent harmful effects of doxorubicin, including neuronal synaptic reduction, apoptosis, neurogenesis impairment, oxidative stress and cognitive impairment. The treatment with the 5-ALA or Bach1 inhibitor can enhance Nrf2 activation, reduce oxidative stress response, mitochondrial dysfunction and doxorubicin-induced neuron death. Research results of the invention show that a new strategy for resisting oxidative stress is represented by using 5-ALA to target a Bach1 / Nrf2 pathway, and a powerful neuroprotection effect is provided for doxorubicin-induced neurotoxicity.
Owner:JINING NO 1 PEOPLES HOSPITAL (JINING ACAD OF MEDICAL SCI)

Nitrogen-containing heterocyclic compound having nrf2 activation effect

Provided is a low-molecular compound or a salt thereof, or a solvate thereof which has the ability to activate Nrf2. The present invention provides a compound represented by the formula (1) or a salt thereof, or a solvate thereof, wherein Xa1 is CRa1 or N, Xa3 is CRa3 or N, Ra1, Ra2 and Ra3 are each independently selected from the group consisting of hydrogen, halogen and C1-C6 alkoxy, Xb1, Xb2 and Xb3 are each independently selected from the group consisting of CH2, O, NH, S and C=O, Y is C6-ClO aryl optionally having a substituent or 5- to 10-membered heteroaryl optionally having a substituent, and Z is C6-ClO aryl optionally having a substituent, 5- to 10-membered heteroaryl optionally having a substituent or C1-C6 alkyl optionally having a substituent.
Owner:CHUGAI PHARMA CO LTD

Highly efficient nrf2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation

ActiveUS20180258121A1AntipyreticAnalgesicsNrf2 activationCo release
The present invention relates to highly efficient Nrf2 activators-CO-releasing molecules of formula (I) and (II) capable of increasing HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases, wherein CORM represents a carbonyl metal complex chosen from among: Mn(CO)5, formula (III), (IV), (V), (VI), (VII), (VIII) and (IX).
Owner:CENT NAT DE LA RECHERCHE SCI +2